Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $94.58 in the prior trading day, Verona Pharma Plc ADR (NASDAQ: VRNA) closed at $90.48, down -4.33%. In other words, the price has decreased by -$4.33 from its previous closing price. On the day, 1.83 million shares were traded. VRNA stock price reached its highest trading level at $97.44 during the session, while it also had its lowest trading level at $89.78.
Ratios:
Our goal is to gain a better understanding of VRNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.73 and its Current Ratio is at 8.86. In the meantime, Its Debt-to-Equity ratio is 1.08 whereas as Long-Term Debt/Eq ratio is at 1.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on July 01, 2025, initiated with a Outperform rating and assigned the stock a target price of $170.
On April 28, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $100.
On April 21, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $80.Cantor Fitzgerald initiated its Overweight rating on April 21, 2025, with a $80 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 16 ’25 when Fisher Andrew sold 80,000 shares for $11.53 per share. The transaction valued at 922,000 led to the insider holds 359,999 shares of the business.
Hahn Mark W sold 400,000 shares of VRNA for $4,560,360 on Jun 11 ’25. The Chief Financial Officer now owns 12,278,992 shares after completing the transaction at $11.40 per share. On Jun 11 ’25, another insider, ZACCARDELLI DAVID, who serves as the President and CEO of the company, sold 400,000 shares for $11.40 each. As a result, the insider received 4,560,520 and left with 13,190,168 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 7688890880 and an Enterprise Value of 68804984832. For the stock, the TTM Price-to-Sale (P/S) ratio is 64.97 while its Price-to-Book (P/B) ratio in mrq is 33.99. Its current Enterprise Value per Revenue stands at 580.461 whereas that against EBITDA is -514.849.
Stock Price History:
The Beta on a monthly basis for VRNA is 0.24, which has changed by 4.759389 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, VRNA has reached a high of $99.01, while it has fallen to a 52-week low of $14.15. The 50-Day Moving Average of the stock is 14.86%, while the 200-Day Moving Average is calculated to be 63.72%.
Shares Statistics:
The stock has traded on average 1.41M shares per day over the past 3-months and 1059910 shares per day over the last 10 days, according to various share statistics. A total of 85.13M shares are outstanding, with a floating share count of 76.70M. Insiders hold about 9.90% of the company’s shares, while institutions hold 76.29% stake in the company. Shares short for VRNA as of 1749772800 were 8415794 with a Short Ratio of 5.96, compared to 1747267200 on 8068371. Therefore, it implies a Short% of Shares Outstanding of 8415794 and a Short% of Float of 10.31.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
